Rentokil Initial heads into Thursday's Q1 trading update with a notably sharp build in short positions — the most striking feature in an otherwise quietly recovering stock.
The short interest picture has changed decisively in the past two weeks. Estimated short shares have jumped roughly 65% since April 21, pushing the total to around 4.16 million shares by April 30. That move accounts for most of the 46% week-on-week rise in short interest, and the ORTEX short score has climbed steadily from 35 to 41 over the same window — still moderate in absolute terms, but the direction of travel is clearly accelerating heading into the event. Despite the sharp rise in positioning, borrow costs remain low at about 1.05% annualised — barely changed over the month — and availability is nowhere near tight, meaning the new shorts have been easy and cheap to put on. Borrow demand is rising, but it is not yet a stressed short.
The options market tells a different story: call activity has been dominant. The put/call ratio sits at just 0.21, well below its 20-day average of 0.26, and close to the lower end of its year-long range. That points to heavier relative demand for upside exposure rather than hedging protection into the release — a contrast with the short sellers adding on the other side.
Bulls can point to a genuine recovery in the share price — up more than 7% over the past month to $33.79 — and a forward EPS growth trajectory that ranks in the top quintile of the market (83rd percentile year-on-year increase). The company carries net debt of around $3.4bn, and the EV/EBITDA multiple has crept higher over the past 30 days, but remains manageable at roughly 13x. BlackRock filed an amended 13G/A at the end of April reflecting a position of 323 million shares — just over 12.8% of the company — and activist investor Trian Fund Management holds a steady 2.3% stake, which has been unchanged in recent filings. For bears, the EV/EBIT ratio ranks in the 10th percentile of its universe on the factor model, flagging a market still paying up for a business whose operating profitability profile has been under scrutiny since the Terminix integration. CEO Michael Duffy bought 16,000 shares at $30.96 back in March — a modest but unambiguous signal at the time — adding to a net insider-buying position of just under $600k over the past 90 days.
One piece of recent corporate activity worth noting: on April 23, Rentokil announced the issuance of $500 million in 4.625% notes due 2031. That adds to the debt load and may sharpen investor focus on leverage reduction progress and free cash flow generation in the statement. The earnings print will test whether the North American pest control business — the main drag on margins since the Terminix deal closed — is showing convincing progress on the route density and efficiency targets management has flagged repeatedly since 2024.
See the live data behind this article on ORTEX.
Open RTO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
